BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Mechanism of Action
P-Selectin Blockers
Pharmacologic Class:
Selectin Blocker
Clinical Trials (5)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Started Oct 2024
315 enrolled
Sickle Cell Disease
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
Started Jul 2024
30 enrolled
Sickle Cell Disease
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
Started Dec 2022
376 enrolled
Sickle Cell Disease
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
Started Aug 2022
31 enrolled
Sickle Cell Disease
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
Started Nov 2021
44 enrolled
Sickle Cell Disease